glp 1 agonist and blindness Ozempic Blindness: Should You Worry? glp-1_analogs [TUSOM | Pharmwiki]

The trial was conducted in parallel in Japan, France, England, Mexico, Denmark, the USA and Germany as part of an international, randomized, double-blind study

They have come into the limelight after a large double-blinded study published in NEJM, showed an average 14.9% dec

The clinical results so far are hard to ignore

Oral semaglutide at doses of up to 14 mg daily is approved for T2D and doses as high as 50 mg daily have been evaluated for weight loss, with 25 mg daily filed for approval for the treatment of obesity.

Despite the potential clinical benefits of GLP-1RA plus SGLT2i combination therapy in patients with T2DM, several factors may delay this combination to become a common practice soon, such as reimbursement and costs associated with polypharmacy

They are known to: - Lower blood sugar without causing hypoglycemia